Cargando…
Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome
Elevated LDL-cholesterol (LDL-C) plays a major role in atheroma formation and inflammation. Medical therapy to lower elevated LDL-C is the cornerstone for reducing the progression of atherosclerotic cardiovascular disease. Statin therapy, and more recently, other drugs such as proprotein convertase...
Autores principales: | Mensink, F. B., Los, J., Ten Cate, T. J. F., Oemrawsingh, R. M., Brouwer, M. A., El Messaoudi, S., van Royen, N., Cornel, J. H., Riksen, N. P., van Geuns, R. J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772027/ https://www.ncbi.nlm.nih.gov/pubmed/36568547 http://dx.doi.org/10.3389/fcvm.2022.1061346 |
Ejemplares similares
-
Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
por: Melendez, Quantil M., et al.
Publicado: (2020) -
Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
por: Wu, Qingyu, et al.
Publicado: (2022) -
Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
por: Suur, Bianca E., et al.
Publicado: (2022) -
Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022) -
Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2023)